FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Other EventsItem 8.01 Other Events.
On January 30, 2018, Fibrocell Science, Inc. (the "Company") issued a press release announcing the Company had obtained FDA allowance to initiate pediatric enrollment in the Phase 1/2 Clinical Trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Description |
|
Press Release dated January 30, 2018.
|
Fibrocell Science, Inc. ExhibitEX-99.1 2 a012918finalreleasefcx00.htm EXHIBIT 99.1 a012918finalreleasefcx00
Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial
of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
EXTON,…To view the full exhibit click here
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.